Testosterone replacement therapy has moved from the margins of men's health into the mainstream. With it has come a question that a growing number of men in their forties and fifties are asking their doctors: will TRT make me go bald? The honest answer is nuanced — but the underlying biology is well understood, and the options for managing hair loss while remaining on testosterone therapy are more robust than many patients realise.
A Rising Tide: TRT Prescribing in Men Over 40
The prescribing of exogenous testosterone has increased dramatically over the past two decades. A landmark analysis published in JAMA Internal Medicine found that testosterone prescriptions in the United States tripled between 2001 and 2011, with the most substantial increase occurring in men aged 40 to 64.1 A parallel UK audit similarly documented an epidemic of testosterone prescribing between 2001 and 2010, driven largely by increased recognition of late-onset hypogonadism and the broader cultural normalisation of TRT as a tool for optimising energy, libido, body composition, and mood.2
This trend reflects both genuine clinical need and, in some cases, aggressive direct-to-consumer marketing. The result is a large and growing population of men receiving supraphysiological or high-physiological testosterone concentrations — and with that comes increased androgenic stimulus to tissues that are, in genetically susceptible individuals, primed to respond badly to it. Chief among these is the hair follicle.
The Conversion Pathway: Testosterone to DHT
To understand why TRT accelerates hair loss, it is necessary to understand what happens to exogenous testosterone after it enters circulation. Testosterone does not act solely as itself. A meaningful proportion is converted peripherally by the enzyme 5α-reductase into dihydrotestosterone (DHT) — a metabolite that is approximately five times more potent at the androgen receptor than testosterone, and which dissociates from that receptor far more slowly, producing a more sustained androgenic signal.3
Two isoforms of 5α-reductase are clinically relevant. Type 1 is expressed predominantly in the skin and liver; type 2 is highly expressed in the genital skin, prostate, and — critically — the hair follicles of the scalp.4 In healthy adult men, approximately 6–8% of circulating testosterone is converted to DHT under normal physiological conditions. When exogenous testosterone is introduced, and total testosterone levels rise, DHT levels rise proportionally — or, in some delivery systems, disproportionately.5
Via injection, transdermal gel, patch, pellet, or cream — serum testosterone rises.
Peripheral tissues — particularly skin and scalp follicles — convert a proportion of testosterone to DHT via 5α-reductase type 1 and type 2.
In the dermal papilla of genetically susceptible scalp follicles, DHT binds androgen receptors with high affinity and sustained receptor occupancy.
Androgenic signalling progressively shortens the anagen (growth) phase and miniaturises the follicle over successive hair cycles, producing pattern hair loss.
It is worth noting that DHT serum levels vary considerably by TRT delivery method. Injectable testosterone — particularly testosterone cypionate and enanthate — tends to produce higher peak DHT levels than transdermal preparations, owing to the bolus-release pharmacokinetic profile and the high hepatic and skin 5α-reductase exposure at peak concentrations.5 This distinction has clinical relevance when managing patients with concurrent hair loss concerns, though the evidence base comparing individual formulations on hair-loss outcomes specifically remains limited.
TRT does not cause hair loss in every man — but in those with a genetic predisposition to androgenetic alopecia, it can unmask or accelerate a process that was already underway.
What the Evidence Shows
The relationship between TRT and androgenetic alopecia is biologically plausible and clinically observed, but the specific trial literature documenting TRT-induced hair loss as a primary endpoint is limited. Hair loss has consistently appeared as an adverse effect in testosterone therapy studies — but it is rarely the primary outcome measured, making incidence estimates imprecise.
What the literature does establish clearly is the mechanistic link. Randall's authoritative review of androgens and hair growth confirms that DHT is the principal mediator of follicular miniaturisation in scalp follicles, operating through androgen receptor-mediated shortening of the anagen phase and upregulation of transforming growth factor beta (TGF-β), a known inhibitor of hair follicle growth.6 Kaufman's review in Molecular and Cellular Endocrinology confirms that this process is amplified in individuals carrying androgen receptor gene polymorphisms on the X chromosome — which explains the well-documented maternal inheritance pattern of androgenetic alopecia and the wide inter-individual variability in response to androgen exposure.7
A systematic review by Nestor et al. in the Journal of Cosmetic Dermatology noted that TRT is a recognised exacerbating factor for androgenetic alopecia in genetically predisposed men, and emphasised that this risk should be disclosed in informed consent discussions prior to initiating therapy.8 Importantly, the same review confirmed that hair loss in this context is not inevitable — genetic predisposition remains the primary determinant of whether an individual's scalp follicles respond adversely to elevated androgens.
Treatment Options for Men on TRT
Managing hair loss in men receiving testosterone therapy requires a concurrent approach — addressing the androgenic stimulus at the follicular level while maintaining the patient's TRT. Ceasing testosterone therapy is rarely appropriate or necessary for hair preservation alone, and most patients would be unwilling to do so. Fortunately, the treatment options available are effective and can be used safely alongside TRT.
5α-Reductase Inhibitors
Finasteride (1 mg daily) selectively inhibits type 2 5α-reductase, reducing scalp DHT by approximately 60–70%.9 Dutasteride (0.5 mg daily) inhibits both type 1 and type 2 isoforms, achieving approximately 90% DHT suppression and demonstrating superior hair count outcomes in head-to-head RCTs.10 Both can be used concurrently with TRT. The trade-off is a modest elevation in serum testosterone (as less is converted to DHT), which is typically clinically insignificant and often desirable in men already on replacement therapy.
Minoxidil
Topical minoxidil (2–5%) applied once or twice daily, or oral low-dose minoxidil (0.625–2.5 mg daily), promotes follicular survival through KATP channel opening, enhanced follicular vasodilation, and telogen-to-anagen phase conversion. It does not affect DHT concentrations but acts independently at the follicular level, making it an effective adjunct in TRT patients.11
Topical DHT Blockers
Topical finasteride formulations — typically 0.1% applied to the scalp — have demonstrated meaningful reductions in scalp DHT with significantly lower systemic absorption than oral preparations. Early trial data suggest comparable scalp DHT suppression with a substantially reduced risk of systemic sexual side effects, making this an emerging option for men with TRT-related hair loss concerns who are cautious about oral 5-ARI side effects.9
TRT Formulation Review
Discussing the delivery method with the prescribing physician may be warranted. Transdermal gels and creams tend to produce more stable testosterone and DHT levels than high-dose intramuscular injections, potentially reducing peak androgenic stimulus to the scalp. Adjustment of protocol should always be made in consultation with the treating clinician and not unilaterally.5
Combination Approaches and Practical Considerations
In clinical practice, the most effective approach for men on TRT who are experiencing androgenetic alopecia is combination therapy: a 5α-reductase inhibitor to reduce DHT conversion at the follicular level, plus minoxidil (topical or oral) to promote follicular survival through an androgen-independent mechanism. This combination is supported by the broader androgenetic alopecia literature — a systematic review in the Journal of Dermatological Treatment confirmed that combination therapy consistently outperforms either agent used alone.9
It is also worth having a transparent conversation with patients about genetic susceptibility. A man with no family history of androgenetic alopecia who initiates TRT is at considerably lower risk of clinically significant hair loss than one with a strongly positive paternal and maternal family history. Baseline scalp photography and annual monitoring are reasonable in susceptible individuals, allowing treatment to be introduced early — when follicular rescue is most achievable — rather than after extensive miniaturisation has already occurred.
Finally, patients should be aware that cessation of TRT does not guarantee reversal of any hair loss that has already occurred. Follicular miniaturisation, once established, is not readily reversed by simply removing the androgenic stimulus. This is another reason why proactive management — commencing hair loss treatment at the time of TRT initiation in susceptible men — is preferable to a reactive approach.
References
- Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465–1466.
- Gan EH, Pattman S, Pearce HS, et al. A UK epidemic of testosterone prescribing, 2001–2010. Clin Endocrinol (Oxf). 2013;79(4):564–570.
- Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology. 1990;126(2):1165–1172.
- Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest. 1993;92(2):903–910.
- Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels. Endocr Rev. 2017;38(3):220–254.
- Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21(5):314–328.
- Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198(1–2):89–95.
- Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759–3781.
- Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Finasteride for hair loss: a systematic review. J Dermatolog Treat. 2022;33(4):1867–1875.
- Jimenez-Cauhe J, Ortega-Quijano D, Rodrigues-Barata R, et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol. 2021;85(3):756–759.
- Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385.